Brazilian federal prosecutors have opened an investigation into a contract worth 1.6 billion reals ($320m) for 20 million doses of a COVID-19 vaccine made by India’s Bharat Biotech, according to a document seen by Reuters.
The prosecutor-general’s office (PGR) cited comparatively high prices, speedy talks and pending regulatory approvals as red flags for the Bharat contract signed in February, before similar deals with Pfizer Inc and Johnson & Johnson.
Keep readinglist of 4 items
Bharat did not respond to a request for comment outside of business hours in India.
The Bharat contract has also drawn scrutiny from a Brazilian Senate inquiry, which called for testimony on Wednesday from the head of Precisa Medicamentos, Bharat’s intermediary in Brasilia.
Justifying the preliminary probe, prosecutors flagged in a document dated June 16 that Precisa’s partners include Global Saude, a company accused of selling but not delivering medicine to the Ministry of Health in a case under investigation by police.
Precisa said it had no knowledge of the prosecutors’ probe and it was open to cooperating with Senate investigators. In a statement, the company said its talks with the health ministry were transparent and the price of Bharat’s vaccine in Brazil was the same charged in more than a dozen other countries.
The Ministry of Health said in a statement on Tuesday that no payment of any kind had been made to Precisa and that its legal department was analysing the case.
Global Saude did not immediately respond to requests for comment.
Prosecutors questioned why the Ministry of Health had agreed to buy the Bharat vaccine, which had not cleared regulatory hurdles, for about $15 per dose: significantly more than what it paid for Pfizer’s vaccine, which had regulatory approval.
“The history of irregularities involving partners at Precisa and the elevated price paid for the doses under contract … require deep investigation in both civil and criminal aspects,” wrote prosecutors.
In a separate document seen by Reuters, Senate investigators cited testimony from an unnamed public servant describing “abnormal pressures” from senior health ministry officials to reach a deal for the Bharat vaccine, branded Covaxin.
In March, Brazilian health regulator Anvisa rejected a request from the government to import doses of Covaxin, citing concerns about Bharat’s manufacturing standards, as well as a lack of safety data and other documentation.
This month, Anvisa’s board agreed to allow the import of just four million Covaxin doses for further study of its safety and effectiveness, but the Ministry of Health must first sign an agreement with the regulator on key conditions.